Disclosed are 8-oxy quinoline compounds of formula I, salts thereof, and methods for their preparation. Specific examples of compounds of formula I include: 1-{ 4-Chloro-3-[4-(4-fluoro-pyrazol-1-yl)-2-methyl-quinolin-8-yloxymethyl]-6-methylpyridin-2-ylmethyl} -2-oxo-1,2-dihydro-pyridine-3-carbonitrile, 1-{ 3-[4-(5-Chloro-thiazol-4-yl)-2-methyl-quinolin-8-yloxymethyl]-4-methyl-pyridin-2-ylmethyl} -3-trifluoromethyl-1H-pyridin-2-one, N-(5-{ 8-[4-Chloro-2-(2-oxo-3-trifluoromethyl-2H-pyridin-1-ylmethyl)-pyridin-3-ylmethoxy]-2-methyl-quinolin-4-yl} -1H-pyrazol-4-ylmethyl)-acetamide, and 1-{ 4-Chloro-3-[4-(4-hydroxy-1H-pyrazol-3-yl)-2-methyl-quinolin-8-yloxymethyl]-6-methyl-pyridin-2-ylmethyl} -2-oxo-1,2-dihydro-pyridine-3-carbonitrile. Also disclosed is the use of compounds of formula I for inhibiting binding of BK to a BK B2 receptor and the use of detectably labelled compounds of formula I for localizing or detecting a BK B2 receptor in a tissue. Compounds of formula I are useful for treating skin disorders eye diseases ear diseases mouth, throat and respiratory diseases gastrointestinal diseases liver, gallbladder and pancreatic diseases urinary tract and kidney diseases diseases of male genitale organs and female genitale organs diseases of the hormone system metabolic diseases cardiovascular diseases blood diseases lymphatic diseases disorders of the central nervous system brain disorders musculoskeletal system diseases allergy disorders pain infectious diseases inflammatory disorders injuries immunology disorders cancers hereditary diseases or edema.
